You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

New Evidence to Assess the Efficacy and Safety of DOACs for the Treatment of NVAF

Authors: Christopher B. Granger, MD; Gregory Y.H. Lip, MD; Roxana Mehran, MD; Renato D. Lopes, MD, PhDFaculty and Disclosures


Posted: 28/5/2019

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and pulmonologists.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Use of antithrombotic therapy for patients with NVAF and concomitant coronary artery disease
    • The efficacy, safety, and cost-benefit of DOACs for the management of patients with NVAF
  • Have greater competence related to
    • The selection of DOACs for the management of patients with NVAF considering patient- and disease-related factors

Contents of This Activity

All sections of this activity are required for credit.

Antithrombotic Management in Patients With NVAF: What Is the Clinical Landscape?

Dr Granger introduces the program and discusses antithrombotic management in NVAF.
Christopher B. Granger, MD

Antithrombotic Strategies for the Management of Patients With NVAF and CHD

Dr Lip reviews the complexity of antithrombotic treatment in patients with NVAF and CHD.
Gregory Y.H. Lip, MD

DOACs in Patients With NVAF Undergoing PCI: Efficacy and Safety

Dr Mehran outlines DOAC use in patients with AF and undergoing PCI.
Roxana Mehran, MD

Apixaban in Patients With AF and ACS and/or PCI: Results of the AUGUSTUS Trial

Dr Lopes presents AUGUSTUS trial results and Dr Granger concludes the program.
Renato D. Lopes, MD; Christopher B. Granger, MD